Medication info

Idiangduo Tablet 12.5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
IlYang Pharmaceutical Co., Ltd.
Appearance
Light brownish-purple, biconvex oval film-coated tablet
Packaging
60 tablets/box [10 tablets/PTP x 6], 10 tablets/box [10 tablets/PTP x 1], 60 tablets/bottle
Approval status
Active

MFDS item code 202302579 · Approved 2023.08.30

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. For patients who do not achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their current doses of empagliflozin and metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; if this occurs, skip the missed dose. No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, item 2)). In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
IlYang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication is used in adults with type 2 diabetes in combination with dietary and exercise therapy to improve blood sugar control. It is particularly suitable for patients whose blood sugar is not adequately controlled, and caution is required in cases with cardiovascular disease. Thus, this medication is used to effectively control blood sugar levels and aid in the health management of patients with type 2 diabetes.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. For patients who do not achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their current doses of empagliflozin and metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; if this occurs, skip the missed dose. No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, item 2)). In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication can cause severe lactic acidosis, so patients must consult a doctor immediately if symptoms of lactic acidosis such as fatigue, myalgia, shortness of breath, weakness, or abdominal pain occur. When used in combination with insulin or sulfonylurea medications, the risk of hypoglycemia may increase, necessitating careful monitoring of blood sugar status and adjustment of medication dosage if needed. This medication should not be administered to patients with moderate to severe renal impairment or acute renal failure, and regular kidney function tests should be performed. Treatment should be discontinued in acute diseases such as severe infections, dehydration, heart failure, and acute myocardial infarction, and can be resumed once the condition improves. If a patient is to undergo a test using iodinated contrast media, this medication should be stopped for at least 48 hours before and after the test, and it should be resumed only after confirming normal kidney function. Pregnant women or those who may become pregnant, as well as nursing mothers, should not use this medication, and it is important to consult a doctor regarding pregnancy plans. During treatment with this medication, caution must be taken to avoid fluid loss, and immediate medical attention should be sought for symptoms such as diarrhea, vomiting, or dehydration. This medication may increase the risk of genitourinary and urinary tract infections, so prompt treatment is necessary if any infection symptoms develop. Long-term use may decrease vitamin B12 levels, and regular blood tests should be performed to monitor vitamin status. Elderly patients or those with decreased kidney function should have their dosage adjusted and kidney function checked frequently, and it is advisable to avoid the maximum dose. In cases of overdose, serious side effects such as lactic acidosis may occur, so it is essential to adhere strictly to the dosage and visit a hospital immediately in case of overdose. Alcohol intake should be avoided during treatment with this medication, as alcohol may increase the risk of lactic acidosis. Symptoms of hypoglycemia can occur particularly when used in combination with other antidiabetic agents, so appropriate measures should be taken if symptoms arise. Safety and efficacy have not been established for this medication in pediatric patients, and it is recommended not to use it in individuals under 18 years of age. Regular medical consultations and examinations are necessary during treatment, and immediate consultation with medical personnel should occur if any abnormal symptoms arise.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
Show 150 more
  • abnormal liver function tests
  • hepatitis
  • taste alteration
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • lower gastrointestinal bleeding
  • chronic gastritis
  • constipation
  • gastritis
  • abdominal discomfort
  • anal incontinence
  • dry mouth
  • gastrointestinal disorders
  • gastroesophageal reflux disease
  • oral discomfort
  • salivary gland pain
  • headache
  • sensory impairment
  • orthostatic dizziness
  • dizziness
  • cerebral infarction
  • drowsiness
  • facial paralysis
  • CNS-origin dizziness
  • fatigue
  • peripheral edema
  • facial edema
  • peripheral swelling
  • fever
  • facial swelling
  • chills
  • strange sensation
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • chest pain
  • weight loss
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • hypertension
  • insomnia
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • conjunctival hyperemia
  • pathologic myopia
  • retinal detachment
  • retinal plaques
  • retinal vein occlusion
  • macular retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • cough
  • dyspnea
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • otalgia
  • orthostatic dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • constipation
  • diarrhea
  • dyspepsia
  • abdominal pain
  • nausea
  • gastritis
  • gastrointestinal disorders
  • nasopharyngitis
  • herpes zoster
  • dizziness
  • headache
  • chest discomfort
  • chest pain
  • weakness
  • weight loss
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyperglycemia
  • back pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Light brownish-purple, biconvex oval film-coated tablet

Package unit

60 tablets/box [10 tablets/PTP x 6], 10 tablets/box [10 tablets/PTP x 1], 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.